S
Suzhou Kintor Pharmaceuticals
Kintor is a pharmaceutical research company
About Suzhou Kintor Pharmaceuticals
Kintor Pharmaceutical, a clinical-stage biopharmaceutical company, was established in Suzhou, China, in 2009. The company was founded by Dr. Youzhi Tong, who currently serves as the Chairman and CEO. Dr. Tong has over 25 years of experience in drug research and development, previously holding the position of Vice President at Angion Biomedica Corp. in the United States and serving as an assistant professor at the Albert Einstein College of Medicine. Kintor Pharmaceutical successfully listed on the Hong Kong Stock Exchange in May 2020.
The company's primary focus is on the research and development of novel drugs for androgen receptor (AR)-related diseases, initially concentrating on oncology indications like prostate, breast, and liver cancer. Its pipeline includes small-molecule drugs, biologics, and combination therapies. Key drug candidates have included Proxalutamide for metastatic castration-resistant prostate cancer and Pyrilutamide (KX-826) for androgenic alopecia and acne. However, after facing setbacks in clinical trials for its oncology and COVID-19 drug candidates, Kintor has strategically shifted its focus. The company is now prioritizing the development and commercialization of treatments for dermatological conditions, such as hair loss and acne. This pivot includes a dual strategy of pursuing regulatory approval for prescription drugs while also marketing over-the-counter cosmetic products to generate early revenue. In 2024, the company recorded its first revenue from its cosmetic brand, Koshiné.
Kintor operates a globally integrated research and development platform with teams in Suzhou, Shanghai, and the United States. To support its commercialization efforts, the company has a modern manufacturing facility in Suzhou Industrial Park, designed in accordance with international GMP standards. This strategic shift towards dermatology and cosmetics aims to leverage their expertise in the AR signaling pathway while navigating the capital-intensive nature of oncology drug development. The company is developing both topical and oral drug candidates and is also exploring the commercialization of functional raw materials for cosmetics, such as for skin whitening and freckle removal.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
Growth signals
Latest recorded traffic for Suzhou Kintor Pharmaceuticals is 10K monthly website visits, down 37.5% over the last three months. Suzhou Kintor Pharmaceuticals's team grew 14.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Suzhou Kintor Pharmaceuticals in its local ecosystem
The Suzhou Kintor Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later4 investors entered at this stage
Green Pine Capital- FFFTZ Fund
Highlight Capital
CCB International
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Suzhou Kintor Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Suzhou Kintor Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









